Jobs / United States / Sanofi US Services INC

HEVA Dupixent Business Partner Respiratory Diseases

Sanofi US Services INC · 🇺🇸 2 Locations

Sponsorship verdict

Sponsorship possible

One solid signal, not two — worth applying, and worth asking about sponsorship early.

  • Employer is on a government sponsor recordThe US Department of Labor certified 47 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 29 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
  • The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
  • No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
  • What Sanofi US Services INC paid sponsored hires in similar roles1 certified filing for “HEVA Bsns Partner-Respiratory & GI Indications, Rhinology Ld” (Management Analysts) in MA: $179k–$179k, median $179k. Most were filed at wage level III (100%) — 3 lottery entries, ≈46% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
  • Confirmed live todayWhen a source last listed this job as open.

US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).

A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.

Start free →

Or apply yourself on the official page →

Sponsor Radar — Sanofi US Services INC

47 H-1B filings certified since Oct 2025

The US Department of Labor certified 47 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 29 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).

Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Sanofi US Services INC →

About the role

Job title :   HEVA Dupixent Business Partner Respiratory Diseases • Location: Cambridge, MA or Morristown, NJ About the Job   Sanofi is an R&D-driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Dupixent (dupilumab) represents one of the most significant advances in the treatment of Type 2 inflammatory diseases in a generation. As a first-in-class biologic targeting the IL-4/IL-13 pathway, Dupixent has transformed the standard of care for patients living with moderate-to-severe asthma and, most recently, Chronic Obstructive Pulmonary Disease (COPD) — becoming the first biologic approved for COPD with a Type 2 inflammatory phenotype. Sanofi is committed to maximizing the full potential of Dupixent across the respiratory space, building a robust and differentiated evidence base that demonstrates its transformative value to patients, payers, and health systems. Through a focused and rapidly expanding body of clinical and real-world evidence, Sanofi aims to address critical gaps in care and deliver meaningful, potentially life-changing treatment options for the millions of patients living with Type 2 inflammatory respiratory conditions who continue to face significant unmet need. This role is primarily focused on Dupixent in COPD and Asthma. Depending on business need, the incumbent may also be called upon to support evidence generation activities for other assets within the respiratory or broader Sanofi portfolio. HEVA Vision, Mission, and Values We are one bold HEOR team leveraging innovative HEOR to transform patient care and access. As HEOR experts, we lead the generation and dissemination of robust, business-relevant evidence to demonstrate value and drive access to medicines. The HEVA organization is driven by five core values that define how we work and deliver impact. We operate as One Team , partnering without boundaries while pursuing a Bold Purpose through ambitious, measurable goals. Grounded in Scientific Excellence with Relevance and deep technical expertise, we embrace Innovation in Action to transform how we research and deliver Impact for People , creating meaningful outcomes for patients, the healthcare ecosystem, and our colleagues who make it all possible. This role is accountable for leading US HEOR strategy and execution for Dupixent in respiratory disease — with a primary focus on COPD and Asthma — serving as the primary US HEVA point of contact for the portfolio and partnering cross-functionally to drive the generation, translation, and dissemination of high-quality, decision-relevant evidence to support access in the United States. The role sits at the heart of one of Sanofi's most strategically significant and commercially important portfolios, requiring a combination of deep scientific expertise in respiratory disease and Type 2 inflammation, strategic thinking, and a sophisticated understanding of the US payer and market access landscape. You will work in the Dupixent Respiratory team of the Health Economics and Value Assessment (HEVA) department. The HEVA department gathers a wealth of expertise including experts in Health Economic and Outcomes Research (HEOR), Indirect Treatment Comparison & Network Meta-Analysis (ITC/NMA), Modelling, Health Te

View the official posting →

Source: Employer career site (Workday) First seen: 2026-08-30 Last confirmed: 2026-10-02 How our data works → Report this job

Similar opportunities